Skip to main content

Rare Diseases

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

Colchicine Benefits COVID-19 Patients

Jul 30, 2020

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies.

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article

Steroids and Tocilizumab in Cytokine Storm Syndrome

Jul 21, 2020

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving

Read Article

RECOVERY Trial: Dexamethasone in COVID-19

Jul 20, 2020

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day

Read Article
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article

Anti-Rheumatic Therapies for COVID-19 Infection

Jul 15, 2020

Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial. The mechanistic effects of these agents, either presumed antiviral, anti-inflammatory and anti-thrombotic effects, may benefit mitigate the damage seen with COVID-19

Read Article

Growing Risk of COVID Among Adolescents

Jul 13, 2020

The risk COVID-19 infection and mortality in the U.S. has been closely correlated with increasing age. However, recent data suggests that young adults (aged 18–25 years) have shown an increasing risk of COVID-19 infection since the pandemic began in March 2020.



Analysis of young

Read Article

COVID's Multisystem Inflammatory Syndrome in Children

Jun 30, 2020

Two recent reports further characterize the newly described, Kawasaki-like,  syndrome affecting children with COVID-19 infections.

The NEJM describes the childhood syndrome as having Kawasaki’s disease, fever, toxic shock syndrome, acute abdominal conditions, and encephalopathy; hence the label

Read Article

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jun 26, 2020

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

ACR Outlines Best Practices for Kids With MIS-C

Jun 25, 2020

Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection has both similarities and differences with Kawasaki disease, and requires distinct clinical management, according to draft guidance from the American College of Rheumatology (ACR).



Age, symptoms,

Read Article

RheumNow Podcast – Enough Already with Weaning (6.19.20)

Jun 19, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article

Cosentyx FDA Approval for Non-Radiographic Axial Spondyloarthritis

Jun 18, 2020

Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab. 

Read Article

Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease

Jun 17, 2020

Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still's disease (AOSD), the first ever FDA approved drug for AOSD.

Canakinumab, an interleukin-1 inhibitor, was FDA approved in 2013 for use children (aged 2 years and older) with systemic juvenile idiopathic

Read Article

Virtual EULAR 2020 Round Up

Jun 12, 2020

In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic

Read Article

Day 3 - Top 5 from EULAR 2020

Jun 10, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

TNR Grand Rounds - Cytokine Storm Syndromes

May 27, 2020

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The

Read Article

Anti-TNF and CNS Events: The Link Strengthens

May 20, 2020

Patients with autoimmune diseases who were treated with tumor necrosis factor (TNF) inhibitors had an increased risk of developing inflammatory central nervous system (CNS) adverse events, a nested case-control study found.

Read Article

Systemic Sclerosis Future Therapies and Outcome Measures

May 19, 2020

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,

Read Article

High Dose Anakinra Effective in COVID-19

May 18, 2020

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared

Read Article

RheumNow Podcast - COVID Kids and Men (5.15.20)

May 15, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

CDC on Pediatric Multi-System Inflammatory Syndrome

May 14, 2020

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Read Article

Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease

May 14, 2020

As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.



In New York, up to 102 children have reportedly developed this inflammatory syndrome, and three

Read Article
×